Jing Li

Jing Li

Auto-generated profile, based on publicly available information

Jing Li

Department of Biochemistry and Molecular Medicine, George Washington University School of Medicine and Health Sciences, Washington, DC

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 August 2018 in Oncogene
Verified
Journal Article
Closed access
PDF file
JSJing Sun
Jing Sun
XCXin Cai
Xin Cai
MYMingo Ming Ho YUNG
Mingo Ming Ho YUNG
WZWei Zhou
Wei Zhou
JLJing Li
Jing Li
WZWenge Zhu
Wenge Zhu

15 March 2019 in Nature Communications
Verified
Journal Article
Open access
PDF file
YPYihan Peng
Yihan Peng
QLQingchao Liao
Qingchao Liao
WTWei Tan
Wei Tan
CPChangmin Peng
Changmin Peng
ZHZhaohua Hu
Zhaohua Hu
HPHuadong Pei
Huadong Pei
Poly-(ADP-ribose) polymerase inhibitors (PARPi) selectively kill breast and ovarian cancers with defects in homologous recombination (HR) caused by BRCA1/2 mutations. There is also clinical evidence for the utility of PARPi in breast and ovarian cancers without BRCA mutations, but the underlying mechanism is not clear. Here, we report that the deubiquitylating enzyme USP15 affects cancer cell response to PARPi by regulating HR. Mechanistically, USP15 is recruited to DNA double-strand breaks (DSBs) by MDC1, which requires the FHA domain of MDC1 and phosphorylated Ser678 of USP15. Subsequently, USP15 deubiquitinates BARD1 BRCT domain, and promotes BARD1-HP1γ interaction, resulting in BRCA1/BARD1 retention at DSBs. USP15 knockout mice exhibit genomic instability in vivo. Furthermore, cancer-associated USP15 mutations, with decreased USP15-BARD1 interaction, increases PARP inhibitor sensitivity in cancer cells. Thus, our results identify a novel regulator of HR, which is a potential biomarker for therapeutic treatment using PARP inhibitors in cancers.

1 August 2018 in Cancer Letters
Verified
Journal Article
Open access
YMYunxiao Meng
Yunxiao Meng
CCChi-Wei Chen
Chi-Wei Chen
MYMingo Ming Ho YUNG
Mingo Ming Ho YUNG
WSWei Sun
Wei Sun
JSJing Sun
Jing Sun
WZWenge Zhu
Wenge Zhu
The acquisition of resistance is a major obstacle to the clinical use of platinum drugs for ovarian cancer treatment. Increase of DNA damage response is one of major mechanisms contributing to platinum-resistance. However, how DNA damage response is regulated in platinum-resistant ovarian cancer cells remains unclear. Using quantitative high throughput combinational screen (qHTCS) and RNA-sequencing (RNA-seq), we show that dual oxidase maturation factor 1 (DUOXA1) is overexpressed in platinum-resistant ovarian cancer cells, resulting in over production of reactive oxygen species (ROS). Elevated ROS level sustains the activation of ATR-Chk1 pathway, leading to resistance to cisplatin in ovarian cancer cells. Moreover, using qHTCS we identified two Chk1 inhibitors (PF-477736 and AZD7762) that re-sensitize resistant cells to cisplatin. Blocking this novel pathway by inhibiting ROS, DUOXA1, ATR or Chk1 effectively overcomes cisplatin resistance in vitro and in vivo. Significantly, the clinical studies also confirm the activation of ATR and DOUXA1 in ovarian cancer patients, and elevated DOUXA1 or ATR-Chk1 pathway correlates with poor prognosis. Taken together, our findings not only reveal a novel mechanism regulating cisplatin resistance, but also provide multiple combinational strategies to overcome platinum-resistance in ovarian cancer.

1 October 2019 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
ZLZhuqing Li
Zhuqing Li
WZWei Zhou
Wei Zhou
YZYi Zhang
Yi Zhang
WSWei Sun
Wei Sun
MYMingo Ming Ho YUNG
Mingo Ming Ho YUNG
WZWenge Zhu
Wenge Zhu
Purpose: Up to 80% of patients with ovarian cancer develop platinum resistance over time to platinum-based chemotherapy. Increased HIF1α level is an important mechanism governing platinum resistance in platinum-resistant ovarian cancer (PROC). However, the mechanism regulating HIF1α stability in PROC remains largely unknown. Here, we elucidate the mechanism of HIF1α stability regulation in PROC and explore therapeutic approaches to overcome cisplatin resistance in ovarian cancer. Experimental Design: We first used a quantitative high-throughput combinational screen (qHTCS) to identify novel drugs that could resensitize PROC cells to cisplatin. Next, we evaluated the combination efficacy of inhibitors of HIF1α (YC-1), ERK (selumetinib), and TGFβ1 (SB431542) with platinum drugs by in vitro and in vivo experiments. Moreover, a novel TGFβ1/ERK/PHD2-mediated pathway regulating HIF1α stability in PROC was discovered. Results: YC-1 and selumetinib resensitized PROC cells to cisplatin. Next, the prolyl hydroxylase domain-containing protein 2 (PHD2) was shown to be a direct substrate of ERK. Phosphorylation of PHD2 by ERK prevents its binding to HIF1α, thus inhibiting HIF1α hydroxylation and degradation—increasing HIF1α stability. Significantly, ERK/PHD2 signaling in PROC cells is dependent on TGFβ1, promoting platinum resistance by stabilizing HIF1α. Inhibition of TGFβ1 by SB431542, ERK by selumetinib, or HIF1α by YC-1 efficiently overcame platinum resistance both in vitro and in vivo. The results from clinical samples confirm activation of the ERK/PHD2/HIF1α axis in patients with PROC, correlating highly with poor prognoses for patients. Conclusions: HIF1α stabilization is regulated by TGFβ1/ERK/PHD2 axis in PROC. Hence, inhibiting TGFβ1, ERK, or HIF1α is potential strategy for treating patients with PROC.

1 June 2015 in DNA Repair
Verified
Journal Article
Closed access
JHJinho Heo
Jinho Heo
JLJing Li
Jing Li
MSMatthew Summerlin
Matthew Summerlin
AHAnnette Hays
Annette Hays
SKSachin Katyal
Sachin Katyal
LHLeslyn A. Hanakahi
Leslyn A. Hanakahi

1 December 2017 in DNA Repair
Verified
Journal Article
Closed access
JLJing Li
Jing Li
MSMatthew Summerlin
Matthew Summerlin
KNKarin C. Nitiss
Karin C. Nitiss
JNJohn L Nitiss
John L Nitiss
LHLeslyn A. Hanakahi
Leslyn A. Hanakahi